Recombinant Human Probable G-protein coupled receptor 146 (GPR146)

What is GPR146 and what are its basic structural features?

GPR146 is a G protein-coupled receptor encoded by the GPR146 gene (also known as PGR8) in humans. It displays the characteristic GPCR architecture, comprising an extracellular N-terminus, seven transmembrane helices that span the cell membrane, and an intracellular C-terminus . This structural arrangement is fundamental to its function as a signaling protein. GPR146 belongs to the Class A (Rhodopsin) Orphan receptor family within the broader GPCR superfamily, which constitutes the most abundant receptor family at the cell surface . The protein consists of 333 amino acids and traverses the membrane seven times, as is typical for GPCRs .

What is the sequence and basic information of human GPR146?

The human GPR146 protein has been thoroughly characterized in terms of its basic properties and sequence information, as detailed in the table below:

The amino acid sequence provides the foundation for structural studies and recombinant protein expression strategies .

What are the known ligands or binding partners of GPR146?

Research has identified proinsulin C-peptide as a potential ligand for GPR146, suggesting this receptor plays a role in C-peptide signaling pathways . C-peptide, a cleavage product generated during insulin biosynthesis, has emerged as a bioactive molecule with therapeutic potential for diabetes-associated complications . The interaction between GPR146 and C-peptide appears to initiate signaling cascades that regulate various cellular functions, particularly in tissues affected by diabetic complications such as the retinal pigment epithelium . Experimental verification of this interaction has included knockdown studies demonstrating that GPR146 depletion blocks C-peptide-induced cFos expression in KATOIII cells, confirming the functional relationship between these molecules .

What are the most effective expression systems for producing recombinant human GPR146?

For recombinant GPR146 production, researchers should consider membrane protein expression challenges when selecting an expression system. Mammalian cell lines (HEK293, CHO) offer proper folding and post-translational modifications crucial for maintaining GPR146's native conformation. For large-scale production, baculovirus-infected insect cells (Sf9, High Five) provide a balance between proper folding and yield. Experimental design should include optimization of expression conditions through temperature modulation (typically 27-30°C for insect cells), induction timing, and detergent screening for solubilization efficiency.

A methodological approach involves testing multiple constructs with various fusion tags (such as His6, FLAG, or GFP) positioned at either the N- or C-terminus, with flexible linkers to maintain receptor functionality. Expression verification should employ Western blotting with tag-specific or GPR146-specific antibodies, complemented by functional assays to confirm the recombinant protein maintains binding capacity to C-peptide. For structural studies requiring higher purity, affinity chromatography followed by size exclusion chromatography in the presence of appropriate detergents or lipid nanodiscs is recommended to maintain the native conformation of the transmembrane domains.

How can I optimize GPR146 knockdown experiments to study its function?

When designing GPR146 knockdown experiments, researchers should employ multiple complementary approaches to ensure robust and specific gene silencing. For siRNA-mediated knockdown, design at least three independent siRNA sequences targeting different regions of GPR146 mRNA and validate knockdown efficiency through both qRT-PCR (for mRNA levels) and Western blotting (for protein expression). The typical effective concentration range is 10-50 nM, but this should be empirically determined for your specific cell type.

For more stable knockdown, CRISPR-Cas9 genome editing offers advantages, particularly for long-term experiments. Design guide RNAs targeting early exons of GPR146 to maximize disruption probability. The experimental design should include appropriate controls: non-targeting siRNA/scrambled gRNA controls, MOCK transfection controls, and positive controls targeting genes with known knockdown phenotypes. After confirming knockdown efficiency (typically aiming for >80% reduction), functional assays should focus on documented GPR146 pathways, including analysis of cFos expression in response to C-peptide stimulation . Additionally, monitor phenotypic changes in retinal epithelial function, inflammation markers, and response to viral challenge, given GPR146's identified roles in these processes .

What binding assays are most appropriate for studying GPR146-ligand interactions?

For studying GPR146-ligand interactions, researchers should implement a multi-modal approach combining biophysical and cell-based techniques. Surface Plasmon Resonance (SPR) offers direct measurement of binding kinetics between purified GPR146 and potential ligands like C-peptide. For this approach, recombinant GPR146 should be immobilized on sensor chips using amine coupling or capture via affinity tags, maintaining the receptor in detergent micelles or lipid nanodiscs to preserve native conformation.

Radioligand binding assays using 125I-labeled C-peptide provide another quantitative approach, allowing calculation of binding affinity (Kd), receptor density, and ligand specificity through competition experiments. These assays can be performed in membrane preparations from cells expressing GPR146 or with purified receptor reconstituted into liposomes. For cellular signaling verification, BRET (Bioluminescence Resonance Energy Transfer) or FRET (Fluorescence Resonance Energy Transfer) assays detect conformational changes upon ligand binding, where GPR146 and interacting G-proteins are tagged with appropriate donor-acceptor pairs.

Functional validation should include downstream signaling measurements like cAMP accumulation, calcium flux, or ERK phosphorylation. The documented ability of GPR146 knockdown to block C-peptide-induced cFos expression provides a reliable readout for confirming functional binding . Researchers should control for non-specific binding and include positive controls (known GPCR-ligand pairs) and negative controls (non-relevant peptides) in all binding experiments.

How does GPR146 contribute to immunomodulation and inflammation?

Recent research has uncovered significant connections between GPR146 and immunomodulatory functions, particularly in the context of non-specific orbital inflammation (NSOI) . Differential expression analysis has identified GPR146 as one of the key genes with altered expression patterns in NSOI compared to control tissues, showing an impressive AUC value of 0.943 in ROC analysis, indicating its potential as a diagnostic biomarker . The mechanistic relationship between GPR146 and inflammation appears to be multifaceted.

Gene Set Enrichment Analysis (GSEA) of GPR146-associated differential gene expression reveals distinct immune signatures. In low GPR146 expression contexts, there is significant enrichment in adaptive immune response pathways, particularly those based on somatic recombination of immune receptors and lymphocyte-mediated immunity . Conversely, high GPR146 expression groups show enrichment in developmental and metabolic pathways rather than immune functions. KEGG pathway analysis further supports this dichotomy, with low GPR146 expression associating with allograft rejection, autoimmune thyroid disease, and graft-versus-host disease pathways .

The inflammatory connection is further strengthened by the observed association between GPR146 and plasma concentrations of C-reactive protein (CRP), a cardinal biomarker for systemic inflammation . This finding is particularly relevant given inflammation's pivotal role in numerous pathological processes, including atherogenesis. The relationship between GPR146 expression and immune cell infiltration in the immune microenvironment suggests this receptor may serve as both a prognostic indicator and a potential therapeutic target for modulating inflammatory responses in conditions like NSOI .

What is the role of GPR146 in diabetes-associated complications and how can it be targeted therapeutically?

GPR146 has emerged as a promising therapeutic target for diabetes-associated microvascular complications through its interaction with proinsulin C-peptide . The mechanistic basis for this therapeutic potential lies in GPR146's ability to regulate the function of retinal pigment epithelium, a critical monolayer of cells in the retina that forms part of the blood-retinal barrier . In diabetic macular edema, this barrier becomes disrupted, contributing to vision impairment.

The GPR146-C-peptide signaling axis appears to exert protective effects on multiple tissues affected by diabetic complications. Research indicates that this interaction has therapeutic potential not only for retinopathies but also for diabetic neuropathies and nephropathy . The molecular mechanism involves C-peptide binding to GPR146, which triggers intracellular signaling cascades that ultimately lead to cellular responses. Experimental evidence shows that knockdown of GPR146 blocks C-peptide-induced cFos expression in cellular models, confirming the specificity of this pathway .

For therapeutic development targeting this interaction, researchers should consider several approaches: (1) enhancing endogenous C-peptide binding to GPR146 through stabilizing agents, (2) developing synthetic GPR146 agonists that mimic C-peptide's beneficial effects, or (3) designing allosteric modulators that enhance receptor sensitivity to physiological C-peptide levels. The tissue-specific expression pattern of GPR146 in retinal, neural, and renal tissues affected by diabetic complications provides potential for targeted therapeutic intervention with reduced systemic effects.

What is the evidence for GPR146's role in antiviral defense?

GPR146 has been identified as an antiviral factor with specificity against RNA virus infections, including Vesicular stomatitis virus and Newcastle disease virus . This antiviral function represents a novel and unexpected role for this GPCR, expanding our understanding of its biological significance beyond metabolic and inflammatory pathways.

The mechanism through which GPR146 exerts its antiviral effects remains under investigation, but several pathways have been implicated through gene set variation analysis (GSVA). Functional alterations in GPR146-associated differentially expressed genes show enrichment in the cytosolic DNA sensing pathway , which typically recognizes foreign nucleic acids and triggers interferon responses. Additionally, enrichment in natural killer cell-mediated cytotoxicity pathways suggests GPR146 may influence innate immune responses to viral infection .

Molecular function analysis further reveals associations with tumor necrosis factor receptor binding and regulation of interleukin-18 production , both of which play roles in antiviral immunity. This multifaceted involvement in immune signaling provides potential mechanistic explanations for GPR146's observed antiviral properties. For researchers investigating GPR146 as an antiviral target, experimental approaches should include:

• Viral challenge models in cells with modulated GPR146 expression

• Analysis of interferon pathway activation in response to viral infection

• Evaluation of GPR146-dependent changes in expression of known antiviral restriction factors

• Assessment of viral replication kinetics in the presence of GPR146 agonists/antagonists

These findings suggest GPR146 could serve as a potential target for antiviral drug development, particularly against RNA viruses .

How should differential expression data for GPR146 be analyzed across different disease contexts?

When analyzing differential expression data for GPR146 across disease contexts, researchers should implement a comprehensive analytical framework that accounts for heterogeneity in expression patterns and potential confounding factors. Begin with robust normalization methods appropriate for your platform (e.g., quantile normalization for microarray data or DESeq2/edgeR normalization for RNA-seq data), followed by batch effect correction using methods like ComBat if samples were processed in different batches.

For differential expression analysis, employ statistical approaches that accommodate the characteristics of your data distribution. The limma package has been successfully used for GPR146 expression analysis in previous studies . Calculate fold changes and statistical significance (adjusted p-values < 0.05) to identify disease-associated alterations in GPR146 expression.

Beyond simple differential expression, researchers should conduct correlation analyses between GPR146 expression and clinical parameters or disease progression metrics. In the context of NSOI, significant correlations between GPR146 expression and immune cell infiltration have been documented . Additionally, receiver operating characteristic (ROC) curve analysis should be performed to assess GPR146's potential as a diagnostic or prognostic biomarker, with area under the curve (AUC) values calculated to quantify discrimination power (GPR146 demonstrated an impressive AUC of 0.943 in NSOI studies) .

For comprehensive interpretation, integrate GPR146 expression data with pathway analysis using tools like Gene Set Enrichment Analysis (GSEA) or Gene Set Variation Analysis (GSVA) to identify biological processes and signaling pathways associated with GPR146 expression changes . This approach revealed distinct immunological signatures in high versus low GPR146 expression groups, with significant enrichment in adaptive immune response pathways in low-expression contexts .

What computational approaches can predict the structure and function of GPR146?

For predicting GPR146 structure and function, researchers should employ a multi-level computational strategy combining homology modeling, molecular dynamics simulations, and machine learning approaches. Begin with sequence analysis tools to identify conserved motifs and functional domains within GPR146's 333 amino acid sequence . For GPCRs, the seven transmembrane domains and their arrangement are particularly important for function prediction.

Homology modeling offers a reliable starting point for structural prediction, using experimentally determined structures of related Class A GPCRs as templates. Multiple template selection improves model quality, particularly for capturing loop regions and binding pockets. The resulting models should undergo refinement through molecular dynamics simulations (100-500 ns) in membrane environments to assess stability and conformational flexibility. These simulations should incorporate appropriate lipid bilayer compositions and be analyzed for metrics like RMSD, RMSF, and potential hydrogen bonding networks.

For ligand binding site prediction, combine sequence conservation analysis with cavity detection algorithms and molecular docking studies using known ligands like C-peptide . Binding energy calculations and interaction fingerprinting can identify key residues involved in ligand recognition. Machine learning approaches like random forest or neural networks can integrate these structural predictions with experimental binding data to develop predictive models for novel ligand discovery.

Functional prediction should leverage coexpression network analysis to identify genes and pathways associated with GPR146. Previous studies identified 113 differentially expressed genes correlated with GPR146 expression , which can guide functional annotation. Orthogonal validation of these computational predictions through experimental methods like site-directed mutagenesis of predicted functional residues is essential for confirming structure-function relationships.

How can researchers integrate multi-omics data to understand GPR146's role in disease pathways?

Integrating multi-omics data to elucidate GPR146's role in disease pathways requires a systematic approach combining genomic, transcriptomic, proteomic, and clinical data. Begin with differential expression analysis of GPR146 across disease and control samples, as demonstrated in NSOI studies where distinct expression patterns were identified . This transcriptomic foundation should be complemented with genomic data analysis, including identification of single nucleotide polymorphisms (SNPs) or genetic variants in GPR146 associated with disease risk or progression.

Protein-level analysis should examine post-translational modifications, protein-protein interactions, and alterations in GPR146 subcellular localization in disease states. Mass spectrometry-based approaches can identify GPR146 interaction partners in different cellular contexts, while proximity labeling methods can map the receptor's immediate protein neighborhood. Metabolomic profiling, particularly focused on lipid mediators and inflammatory metabolites, can reveal downstream consequences of GPR146 signaling alterations.

Network-based integration is crucial for synthesizing these multi-omics datasets. Construct protein-protein interaction networks centered on GPR146, incorporating data from correlation analyses that identified genes with expression patterns linked to GPR146 . Apply pathway enrichment and network propagation algorithms to these integrated networks to identify disease-relevant biological processes. Previous studies using this approach revealed GPR146's connections to immune response pathways, particularly adaptive immunity and lymphocyte-mediated responses .

For visualization and interpretation, dimensional reduction techniques like t-SNE or UMAP can display the multi-dimensional relationships between samples based on their integrated omics profiles. Machine learning approaches, including supervised classification models, can then identify features across omics layers that best predict disease outcomes in relation to GPR146 expression or activity. This integrated approach has successfully identified GPR146 as a potential prognostic marker with connections to immune cell infiltration in the disease microenvironment .

What are the promising therapeutic applications of targeting GPR146?

GPR146 presents several promising therapeutic avenues based on its diverse biological functions. The most advanced application involves targeting the GPR146-C-peptide interaction for treating diabetes-associated microvascular complications . By enhancing or mimicking C-peptide's binding to GPR146, therapeutic interventions could potentially restore function in retinal pigment epithelium affected by diabetic macular edema, where the blood-retinal barrier is disrupted . This approach extends beyond retinopathies to include potential benefits for diabetic neuropathies and nephropathy, all of which share underlying microvascular pathology .

The immunomodulatory functions of GPR146 revealed by recent studies suggest targeting potential in inflammatory disorders, particularly non-specific orbital inflammation (NSOI) . With GPR146 expression strongly correlating with immune cell infiltration patterns, selective modulation could potentially rebalance dysregulated immune responses . The high diagnostic accuracy of GPR146 expression in distinguishing NSOI from control tissues (AUC = 0.943) underscores its relevance to this disease process .

The identification of GPR146 as an antiviral factor specific to RNA virus infections opens another therapeutic frontier . Development of GPR146 agonists could potentially enhance endogenous antiviral responses against pathogens like Vesicular stomatitis virus and Newcastle disease virus . This application might extend to other RNA viruses of clinical significance, though specificity and mechanistic studies are needed.

For all these applications, drug development approaches should include (1) small molecule screening for GPR146 modulators using high-throughput binding and functional assays, (2) structure-based design informed by computational models of GPR146's binding pocket, and (3) biologics development, including modified versions of C-peptide with enhanced pharmacokinetic properties or stability.

How might single-cell technologies advance our understanding of GPR146 in tissue-specific contexts?

Single-cell technologies offer unprecedented opportunities to dissect GPR146's expression patterns and functions across heterogeneous cell populations within tissues. Single-cell RNA sequencing (scRNA-seq) can map GPR146 expression at cellular resolution, revealing specific cell types that predominantly express this receptor in both healthy and disease states. This approach is particularly valuable for tissues like retinal pigment epithelium, where GPR146 has known functional relevance in diabetic complications , or in inflammatory contexts where immune cell subpopulations may differentially express GPR146 .

Beyond expression mapping, single-cell multi-omics approaches combining transcriptomics with proteomics (CITE-seq) or chromatin accessibility (scATAC-seq) can provide insights into regulatory mechanisms controlling GPR146 expression and activity. These methods could identify cell type-specific transcription factors or epigenetic modifications governing GPR146 in different physiological or pathological contexts.

For functional characterization, single-cell resolution signaling analyses using technologies like mass cytometry (CyTOF) with phospho-protein antibodies can track GPR146-mediated signaling cascades at the individual cell level. This would be particularly valuable for understanding how GPR146 activation by C-peptide influences downstream pathways in specific cell populations relevant to diabetic complications .

Spatial transcriptomics technologies add another dimension by preserving tissue architecture while measuring gene expression, allowing researchers to correlate GPR146 expression with microanatomical features. This approach would be especially informative in complex tissues like the retina or in inflammatory lesions of NSOI, where the spatial relationship between GPR146-expressing cells and other tissue components may be functionally significant .

For therapeutic development, single-cell approaches can identify off-target effects of GPR146 modulators across diverse cell types, potentially predicting tissue-specific efficacy or toxicity profiles of candidate compounds.

What challenges remain in developing selective modulators of GPR146 activity?

Developing selective modulators of GPR146 activity presents several significant challenges that researchers must address. First, the three-dimensional structure of GPR146 has not been experimentally determined, limiting structure-based drug design approaches. While computational models based on related GPCRs can provide initial insights, they may not capture unique structural features of GPR146's binding pocket. High-resolution structural determination through cryo-electron microscopy or X-ray crystallography remains a priority for rational drug design.

Second, achieving selectivity for GPR146 over other GPCRs presents a major hurdle. The GPCR superfamily shares structural similarities, particularly within the seven-transmembrane domain architecture . Designing compounds that exclusively target GPR146 requires detailed knowledge of unique binding pocket residues or allosteric sites. Cross-screening against a panel of related GPCRs will be essential to identify truly selective compounds.

Third, understanding the full spectrum of GPR146 signaling represents another challenge. While C-peptide has been identified as a potential ligand , the complete signaling profile, including G-protein coupling preferences and β-arrestin recruitment patterns, remains incompletely characterized. Different signaling pathways may mediate distinct biological effects of GPR146 activation, from effects on retinal pigment epithelium to antiviral responses . Biased ligands that selectively activate beneficial pathways while avoiding potential side effects will require detailed pathway mapping.

Fourth, tissue-specific considerations complicate therapeutic development. GPR146 functions may vary across tissues, with documented roles in retinal pigment epithelium, immune cells, and antiviral responses . Achieving targeted delivery to specific tissues while avoiding systemic effects represents a significant pharmaceutical challenge. Advanced drug delivery systems or prodrug approaches may be needed to achieve tissue selectivity in therapeutic applications.

Finally, appropriate model systems for preclinical validation require careful consideration. Given GPR146's diverse roles in diabetes complications, inflammation, and antiviral defense , selecting disease models that accurately recapitulate human pathophysiology is crucial for translational success.